Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Duolingo: Earnings Panic Created a Tactical Long — Buy the Dip
Q3 noise produced an outsized drop. Fundamentals (and a strong balance sheet) say this is a disciplined buy with defined risk.
Duolingo sold off after a messy Q3 print that included a large tax benefit and some noisy guidance. The business is still growing (Q1-Q3 revenue up se...
Buy the Dip in Centrus (LEU): A Risk-Weighted Swing Into HALEU Optionality
Quarterly noise, a bigger balance-sheet setup, and a policy-fueled market make the recent pullback an asymmetric trade.
Centrus' share price has pulled back after a bout of headline-driven selling. The business still earns most of its revenue from low-enriched uranium (...
Aurora Innovation: Why 2026 Still Isn’t the Year for Autonomous Trucking
Small revenue, big losses, and too much optionality priced in—short-biased trade with defined risk.
Aurora Innovation is promising technology and partnerships, but through 09/30/2025 the company still reports essentially no revenue ($1.0m), quarterly...
Qualcomm: Soft Recent Results Paint a Discounted Opportunity — Tactical Long with Tight Risk Control
Underperformance versus recent highs but solid cash flow, buybacks and a healthy balance sheet keep upside intact — trade the rebound, size it small.
Qualcomm has seen sequential declines in revenue, operating income and EPS through fiscal 2025, and the stock has lagged after a sharp run earlier. St...
Lumen Heading Into 2026: A Volatile Turnaround Trade with Big Balance-Sheet Questions
Catalyst-driven swing trade: play the AI/enterprise momentum but respect the debt and earnings holes
Lumen (LUMN) is a company in transition — shedding legacy consumer assets and leaning into enterprise and AI infrastructure. Recent quarter-to-quart...
Cardiff Oncology (CRDF) in 2026 - Measured Enthusiasm Around Binary Clinical Catalysts
Cash runway, small-cap valuation, and binary clinical readouts argue for a cautious long with strict risk controls.
Cardiff Oncology is a clinical-stage biotech focused on PLK1 inhibition (onvansertib) across RAS-mutated mCRC and other hard cancers. The balance shee...
AST SpaceMobile: Betting on a Premium, Direct-to-Cell Play While Starlink Chases Scale
Actionable long idea - exposure to ASTS ahead of commercialization catalysts; entry, stops, and targets included.
AST SpaceMobile (ASTS) is building a space-based cellular broadband layer that connects directly to unmodified mobile phones. The business is still ea...
Micron at a Peak: Three Structural Risks That Warrant a Short-Hedge Trade
Strong Q1 results mask cyclical, capital-intense and concentration risks — an actionable short-biased swing idea with clear entries, stops and targets.
Micron posted a blowout quarter (Q1 FY2026) with revenues of $13.643B and diluted EPS of $4.60, yet three long-term structural issues - memory cyclica...
Tactical Long on HIVE: Cheap on Price, Still a Bitcoin Beta Trade
Current market moves offer a low entry into a growing miner, but the stock remains tightly coupled to Bitcoin’s rollercoaster.
HIVE Digital trades at roughly $3.46 after a recent bounce; operational expansions (notably a large Paraguay build-out) make the company structurally ...
Alphabet: Buy the AI Crowned Market Leader — Tactical Entry with a Clear Risk-Managed Plan
Gemini, scale in Cloud, and heavy free cash flow make Alphabet a high-conviction AI trade — enter with a stop and two staged targets.
Alphabet (GOOG) is the market's best-positioned incumbent to monetize the next wave of AI. Strong quarterly cash flow (operating cash flow of $48.4B i...
Buy the AI-Inference Trade: Why SanDisk (SNDK) Can Keep Running
NAND tightness + hyperscaler urgency = continued upside. Actionable long trade with entries, stops and stretch targets.
SanDisk's re-listing and sudden re-rise is not a momentum fluke — it is the commodity economics of NAND meeting structural demand from AI inference ...
Don’t Panic — Qualcomm’s 5% Pullback Is a Patient Investor’s Entry Point
Solid cash flows, healthy margins and a steady dividend make QCOM a buy on weakness; trade plan included.
Qualcomm dropped roughly 5% from recent short-term highs to the mid-170s area, creating a low-risk entry for investors who can wait through product cy...